November 26, 2024
TOPLINE: Use of the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and liraglutide is linked to a lower risk for alcohol use disorder (AUD)–related hospitalizations compared […]
November 26, 2024
TOPLINE: Global antipsychotic polypharmacy use increased significantly from 1970 to 2023, with 25% of antipsychotic users receiving multiple prescriptions, new research shows. Antipsychotic polypharmacy was associated […]
November 25, 2024
Repetitive transcranial magnetic stimulation (rTMS) is both safe and effective for treating nonexistent spoken voices heard by patients with schizophrenia, new research showed. In a randomized, […]
November 25, 2024
A report published earlier this year by the US Senate Special Committee on Aging is calling for a national coordinated response to what the authors claim […]
November 22, 2024
Endo USA, Inc, has expanded its previously announced recall of clonazepam orally disintegrating tablets due to a packaging error that could be life-threatening. An ongoing investigation […]
November 21, 2024
Amid substantially rising opioid-related deaths and other harms in Canada, the city of Calgary is grappling with the potential closure of the Sheldon Chumir supervised consumption […]
November 21, 2024
LISBON, PORTUGAL — Almost half of surveyed LGBTQ+ people born in Sweden have experienced perceived discrimination and more than a third have mental health symptoms, according […]
November 20, 2024
Two US Food and Drug Administration (FDA) advisory panels are urging the agency to eliminate the risk management program for the antipsychotic drug clozapine, saying that […]
November 20, 2024
Suicide and self-harm continue to be serious concerns in Europe, despite decreasing rates over the past two decades. In 2021 alone, 47,346 people died by suicide […]